GELITA VERISOL: 44 Women Aged 39-75, 16-Week RCT, Statistically Significant Hair Thickness Gain
INGREDIENTS

GELITA VERISOL: 44 Women Aged 39-75, 16-Week RCT, Statistically Significant Hair Thickness Gain

By Yuna · · https://www.gelita.com/en/news/beyond-skin-first-peer-reviewed-study-reveals-increased-hair-thickness
KO | EN

GELITA’s first peer-reviewed clinical study extended VERISOL collagen peptide’s clinical territory from skin into hair. In a 16-week randomized placebo-controlled trial in 44 women aged 39-75, the group taking 2.5g daily of VERISOL showed a statistically significant increase in hair thickness. The placebo group showed a slight decrease over the same period.

44 women, 39-75 years, 16 weeks

The study’s value lies in its sample composition and duration. The 39-75 age range covers both pre- and postmenopausal women. Because peri- and postmenopausal hormone shifts affect hair cycles, observing a consistent effect across this range is clinically meaningful.

Sixteen weeks is a meaningful evaluation point in the hair cycle. The growth (anagen) phase averages 2-7 years, and the resting (telogen) phase about 3 months. Sixteen weeks is when transitions from telogen back into a new anagen phase begin to accumulate. Detectable thickness differences at this point suggest VERISOL acts on the thickness of newly entering anagen-phase hair.

31% in vitro hair follicle cell proliferation

In vitro data accompanying the clinical results adds support. When human hair follicle cells were treated with VERISOL, proliferation rates increased by 31%. This mechanism data shows the active cell count in the follicle itself increases.

The path from oral collagen peptide to hair follicle is not trivial. After breakdown into tripeptide or dipeptide units in the gut, peptides circulate to the dermis and act in the follicle unit. The 31% proliferation increase is in vitro evidence that this pathway actually operates.

The collagen category sharpens at the mechanism level

The deeper meaning of this trial extends beyond simple efficacy reporting. The collagen peptide category is sharpening at the mechanism level. The general claim “drinking collagen helps skin” is giving way to “this molecular weight peptide acts on these cells through this pathway.”

VERISOL belongs to GELITA’s Bioactive Collagen Peptides® line. With molecular weight tuned to 2-5 kDa, the peptide composition differs from generic hydrolyzed collagen. The molecular weight difference influences absorption efficiency and target cell delivery, which is GELITA’s core claim.

Same-quarter collagen category landscape

This study aligns with other collagen announcements the same quarter. BASF’s January announcement of precision peptide and recombinant collagen III, and Olay’s March AAD presentation of Triple Collagen Peptide. All trace the same arc, from the general term “collagen” to specific peptide compositions and specific cell targets.

A separate study on low-molecular-weight collagen peptide (LMWCP, under 1 kDa) was also published the same quarter. One study reported LMWCP activating the Wnt/GSK-3β/β-catenin pathway to stimulate hair growth, with in vitro proliferation of hair dermal papilla cells (hDPCs) rising 10-30%.

The next stage of category subdivision

Accumulating data signals possible subdivision of the collagen peptide category standard. Hair-targeted formulations may favor different molecular weights and tripeptide content, while skin-dermis-targeted formulations may favor a different composition. The single “collagen supplement” category subdivides into “collagen for skin,” “collagen for hair,” “collagen for joints.”

For consumers, the change is concrete. Labels will move beyond “contains collagen” to specific mechanism-level data: “Bioactive Collagen Peptide at 2-5 kDa molecular weight,” “3% Gly-Pro-Hyp,” “31% human hair follicle cell proliferation.” The collagen category is entering the mechanism era too.